H.C. Wainwright analyst Emily Bodnar raised the firm’s price target on AnaptysBio (ANAB) to $22 from $19 and keeps a Neutral rating on the shares after the company announced Phase 2b topline ...

Guggenheim raised the firm’s price target on AnaptysBio (ANAB) to $52 from $36 and keeps a Buy rating on the shares following the company’s Q4 ...

ANAB remains risky despite new clinical data and partnerships; past successes haven't been replicated, and management's transparency issues raise concerns.

JPMorgan raised the firm’s price target on AnaptysBio (ANAB) to $42 from $36 and keeps an Overweight rating on the shares. The firm updated ...

AnaptysBio (NASDAQ:ANAB – Get Free Report)‘s stock had its “neutral” rating reaffirmed by stock analysts at HC Wainwright in ...

Truist notes that AnaptysBio (ANAB) reported the “much anticipated” results of its Phase 2b trial of rosnilimab for moderate-to-severe rheumatoid arthritis and that the primary endpoint of DAS ...

Has AnaptysBio, Inc. (ANAB) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.

AnaptysBio, Inc. (ANAB) shares rallied 30.5% in the last trading session to close at $16.15. This move can be attributable to notable volume with a higher number of shares being traded than in a ...

AnaptysBio, Inc. (NASDAQ:ANAB – Free Report) – Equities research analysts at Wedbush issued their FY2029 earnings estimates for AnaptysBio in a research report issued to clients and investors ...